Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Nature Medicine (3)
Nature (2)
Eye (1)
Nature Biotechnology (1)
Nature Structural & Molecular Biology (1)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (7)
Correspondence (1)
News & Views (1)

Subject Check one or more subjects to show results from those subjects only.

Biomarkers
Cancer
Computational biology and bioinformatics
Immunology
Medical research

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–9 of 9 results

Advanced filters: Author: Marcus Ballinger Clear advanced filters

Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial

In the IMpower151 trial, the drug combination previously shown to be effective in the IMpower150 trial was not significantly effective in a Chinese population.

Caicun Zhou
Xiaorong Dong
Minu K. Srivastava
ResearchOpen Access16 May 2025
Nature Medicine

P: 1-10
Mapping human visual cortex with positron emission tomography

Peter T. Fox
Mark A. Mintun
David C. Van Essen
Research30 Oct 1986
Nature

Volume: 323, P: 806-809
Semirational design of a potent, artificial agonist of fibroblast growth factor receptors

Marcus D. Ballinger
Venkatakrishna Shyamala
W. Michael Kavanaugh
Research01 Dec 1999
Nature Biotechnology

Volume: 17, P: 1199-1204
An unusual case of ocular self-injury

Marcus Lim
David Kent
David Clark
Correspondence01 Sept 2001
Eye

Volume: 15, P: 660-661
Peripheral T cell expansion predicts tumour infiltration and clinical response

Large-scale single-cell sequencing of RNA and T cell receptors in samples from patients with cancer shows clonotypic expansion of effector-like T cells not only in tumour tissue but also in normal adjacent tissues and peripheral blood, which associates with clinical response to cancer immunotherapy.

Thomas D. Wu
Shravan Madireddi
Jane L. Grogan
Research26 Feb 2020
Nature

Volume: 579, P: 274-278
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

A blood-based DNA sequencing assay to infer tumor mutational burden in the absence of tumor biopsy predicts response to PD-L1 blockade in patients with non-small-cell lung cancer.

David R. Gandara
Sarah M. Paul
David S. Shames
Research06 Aug 2018
Nature Medicine

Volume: 24, P: 1441-1448
Will any dimer do?

Marcus D. Ballinger
James A. Wells
News & Views01 Nov 1998
Nature Structural Biology

Volume: 5, P: 938-940
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients

Treatment with BRAF and/or MEK inhibitors followed by addition of anti-PD-L1 in BRAF-mutant melanoma patients is safe and shows promising anti-tumor activity.

Ryan J. Sullivan
Omid Hamid
Patrick Hwu
Research06 Jun 2019
Nature Medicine

Volume: 25, P: 929-935
MOSBY enables multi-omic inference and spatial biomarker discovery from whole slide images

Yasin Şenbabaoğlu
Vignesh Prabhakar
Kai Liu
ResearchOpen Access06 Aug 2024
Scientific Reports

Volume: 14, P: 1-16